Literature DB >> 23937122

Effect of intracavernous administration of angiopoietin-4 on erectile function in the streptozotocin-induced diabetic mouse.

Mi-Hye Kwon1, Ji-Kan Ryu, Woo Jean Kim, Hai-Rong Jin, Kang-Moon Song, Ki-Dong Kwon, Dulguun Batbold, Guo Nan Yin, Gou Young Koh, Jun-Kyu Suh.   

Abstract

INTRODUCTION: Erectile dysfunction (ED) is a highly prevalent complication of diabetes, and the severity of endothelial dysfunction is one of the most important factors in reduced responsiveness to oral phosphodiesterase type 5 inhibitors. AIM: To study the effects of human angiopoietin-4 (Ang-4) protein on erectile function in diabetic mice.
METHODS: Diabetes was induced by intraperitoneal injection of streptozotocin into 8-week-old C57BL/6J male mice. At 8 weeks after the induction of diabetes, the animals were divided into four groups: control nondiabetic mice and diabetic mice receiving two successive intracavernous injections of phosphate buffered saline (days -3 and 0), a single intracavernous injection of Ang-4 protein (day 0), or two successive intracavernous injections of Ang-4 protein (days -3 and 0). MAIN OUTCOME MEASURES: One week after treatment, we measured erectile function by electrical stimulation of the cavernous nerve. The penis was harvested and stained with hydroethidine or antibodies to Ang-4, platelet/endothelial cell adhesion molecule-1, and phosphorylated endothelial nitric oxide synthase (eNOS). We also determined the differential expression of Ang-4 in cavernous tissue in the control and diabetic mice. The effect of Ang-4 protein on the phosphorylation of Tie-2, Akt, and eNOS was determined in human umbilical vein endothelial cells (HUVECs) by Western blot.
RESULTS: The cavernous expression of Ang-4 was downregulated in diabetic mice; Ang-4 was mainly expressed in endothelial cells. Local delivery of Ang-4 protein significantly increased cavernous endothelial content, induced eNOS phosphorylation, and decreased the generation of superoxide anion and apoptosis in diabetic mice. Ang-4 protein strongly increased the phosphorylation of Tie-2, Akt, and eNOS in HUVECs. Repeated intracavernous injections of Ang-4 induced significant restoration of erectile function in diabetic mice (87% of control values), whereas a single intracavernous injection of Ang-4 protein elicited modest improvement.
CONCLUSIONS: Cavernous endothelial regeneration by use of Ang-4 protein may have potential for the treatment of vascular disease-induced ED, such as diabetic ED.
© 2013 International Society for Sexual Medicine.

Entities:  

Keywords:  Angiogenesis; Angiopoietin-4; Diabetes Mellitus; Endothelial Dysfunction; Enhanced Responsiveness to PDE5 Inhibitors; Erectile Dysfunction; Therapeutic Protein

Mesh:

Substances:

Year:  2013        PMID: 23937122     DOI: 10.1111/jsm.12278

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  10 in total

1.  Angiopoietin-4-dependent venous maturation and fluid drainage in the peripheral retina.

Authors:  Harri Elamaa; Minna Kihlström; Emmi Kapiainen; Mika Kaakinen; Ilkka Miinalainen; Symantas Ragauskas; Marc Cerrada-Gimenez; Satu Mering; Marjut Nätynki; Lauri Eklund
Journal:  Elife       Date:  2018-11-16       Impact factor: 8.140

Review 2.  Molecular mechanisms associated with diabetic endothelial-erectile dysfunction.

Authors:  Ângela Castela; Carla Costa
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

Review 3.  Therapeutic targeting of the angiopoietin-TIE pathway.

Authors:  Pipsa Saharinen; Lauri Eklund; Kari Alitalo
Journal:  Nat Rev Drug Discov       Date:  2017-05-19       Impact factor: 84.694

4.  Inhibition of Ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse.

Authors:  Guo Nan Yin; Min Ji Choi; Woo Jean Kim; Mi-Hye Kwon; Kang-Moon Song; Jin-Mi Park; Nando Dulal Das; Ki-Dong Kwon; Dulguun Batbold; Goo Taeg Oh; Gou Young Koh; Kyu-Won Kim; Ji-Kan Ryu; Jun-Kyu Suh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

5.  Effects of Next-Generation Low-Energy Extracorporeal Shockwave Therapy on Erectile Dysfunction in an Animal Model of Diabetes.

Authors:  Hyun Cheol Jeong; Seung Hwan Jeon; Zhu Guan Qun; Kang Sup Kim; Sae Woong Choi; Fahad Bashraheel; Woong Jin Bae; Su Jin Kim; Hyuk Jin Cho; U Syn Ha; Sung Hoo Hong; Ji Youl Lee; Du Geon Moon; Sae Woong Kim
Journal:  World J Mens Health       Date:  2017-11-20       Impact factor: 5.400

Review 6.  Research in pharmacotherapy for erectile dysfunction.

Authors:  Ji-Kan Ryu; Jun-Kyu Suh; Arthur L Burnett
Journal:  Transl Androl Urol       Date:  2017-04

7.  Gene expression profiling of mouse cavernous endothelial cells for diagnostic targets in diabetes-induced erectile dysfunction.

Authors:  Guo Nan Yin; Jiyeon Ock; Min Ji Choi; Anita Limanjaya; Kalyan Ghatak; Kang Moon Song; Mi Hye Kwon; Jun Kyu Suh; Ji Kan Ryu
Journal:  Investig Clin Urol       Date:  2020-11-09

8.  Vasohibin-1 rescues erectile function through up-regulation of angiogenic factors in the diabetic mice.

Authors:  Kang-Moon Song; Woo Jean Kim; Min-Ji Choi; Ki-Dong Kwon; Anita Limanjaya; Kalyan Ghatak; Jiyeon Ock; Guo Nan Yin; Yasufumi Sato; Soon-Sun Hong; Ji-Kan Ryu; Jun-Kyu Suh
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

9.  Efficient Promotion of Autophagy and Angiogenesis Using Mesenchymal Stem Cell Therapy Enhanced by the Low-Energy Shock Waves in the Treatment of Erectile Dysfunction.

Authors:  Guan Qun Zhu; Seung Hwan Jeon; Woong Jin Bae; Sae Woong Choi; Hyun Cheol Jeong; Kang Sup Kim; Su Jin Kim; Hyuk Jin Cho; U Syn Ha; Sung Hoo Hong; Ji Youl Lee; Eun Bi Kwon; Sae Woong Kim
Journal:  Stem Cells Int       Date:  2018-08-29       Impact factor: 5.443

10.  Angiopoietin-1 Mimetic Nanoparticles for Restoring the Function of Endothelial Cells as Potential Therapeutic for Glaucoma.

Authors:  Raphael Mietzner; Ramona Pawlak; Ernst R Tamm; Achim Goepferich; Rudolf Fuchshofer; Miriam Breunig
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.